Keros Therapeutics (KROS) Treasury Shares (2019 - 2025)

Keros Therapeutics (KROS) reported Treasury Shares of $21.1 million for Q4 2025, up 2827.36% quarter-over-quarter from $721700.0 in Q3 2025.

Keros Therapeutics (KROS) Treasury Shares (2019 - 2025) Analysis & Trends

Keros Therapeutics has reported Treasury Shares for 1 years, with the latest figure at $384.6 million in Q4 2025.

For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $21.1 million; the trailing twelve-month figure through Dec 2025 stood at $21.1 million (changed N/A YoY), and the FY2025 full-year result was $21.1 million, changed N/A from the prior year.
Treasury Shares for Q4 2025 stood at $384.6 million.
The five-year high for Treasury Shares was $21.1 million in Q4 2025, with the low at $721700.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	1.48 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	700,000.00
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Keros Therapeutics	399.01 Mn	111.61 Mn	-	384.56 Mn

Download Data